Discovery of 3-(1<em>H</em>-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- yl]-pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes
Jürgen Wagner(Vogtland-Klinik), Sylvain Cottens, Wilhelm Stark(Novartis (Switzerland)), Peter Matt(Novartis (Switzerland)), Gabriele Rummel(Novartis (Switzerland)), Richard Sedrani(Novartis (Switzerland)), Christian Beerli(Novartis (Switzerland)), Gisbert Weckbecker(Novartis (Switzerland)), André Strauss(Novartis (Switzerland)), Nigel G. Cooke(Novartis (Switzerland)), Jean-Pierre Evenou(Novartis (Switzerland)), Claus Ehrhardt(Novartis (Switzerland)), Rainer Albert, Gerhard Zenke, Sandra W. Cowan-Jacob, Martin Geiser(Novartis (Switzerland))
DORA PSI (Paul Scherrer Institute)
January 1, 2009
Cited by 0
Related Papers
Efficient Aldolase Catalytic Antibodies That Use the Enamine Mechanism of Natural Enzymes
|Science|1995|458
The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation
|Journal of Pharmacology and Experimental Therapeutics|2009|160
Discovery of 3-(1<i>H</i>-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes
|Journal of Medicinal Chemistry|2009|135
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
|Cancer Discovery|2022|134
Sanglifehrin−Cyclophilin Interaction: Degradation Work, Synthetic Macrocyclic Analogues, X-ray Crystal Structure, and Binding Data
|Journal of the American Chemical Society|2003|113